The ITQB groups will work on STING-inhibitor and PFOR enzyme structures for drug development (MATIAS), use SAXS to study E. coli’s Translocated Intimin Receptor and enzyme dynamics (CORDEIRO), target metabolic pathways in pathogens (BRITO & ARCHER), study DNA repair, stress resistance, and iron metabolism (C.V. ROMÃO & MOE), analyze bacterial ligninolytic enzymes (BORGES & FRAZÃO) and examine herpesvirus LANA’s chromatin modulation (MCVEY). The FCT groups will focus on Mo/W enzymes and PHA synthase (M.J. ROMÃO & DE SOUSA MOTA), investigate bacterial cellulosomes and gut microbiome carbohydrate complexes (CARVALHO) and study biofilm inhibitors (SANTOS-SILVA). Finally, the I3S/IBMC groups will examine anticoagulants and drug efflux pumps (PEREIRA), develop structural studies on amyloid proteins and fungal signaling complexes using hybrid approaches (RIBEIRO), study glycosyltransferases in pathogens (CABANES) and explore virulence factors in Photobacterium damselae (Dos SANTOS).